Form 4: Lyell Immunopharma CEO Sells Shares for Tax Cover

Lyell Immunopharma's President and CEO, Lynn Seely, sold 7,455 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Lynn Seely, President and CEO, and a Director of Lyell Immunopharma, Inc. (LYEL), reported a transaction on February 11, 2026.
• Seely disposed of 7,455 shares of Lyell Immunopharma Common Stock.
• The shares were sold at a weighted average price of $23.39 per share, with prices ranging from $23.3939 to $24.7850.
• The sale was conducted to cover tax withholding obligations arising from the settlement of performance-based vested restricted stock units.
• Following this transaction, Lynn Seely beneficially owns 74,266 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transaction is a routine, non-discretionary sale to cover tax obligations, which does not reflect a change in management's confidence or the company's operational performance.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon the vesting of restricted stock units are a routine and common occurrence in executive compensation plans across various industries, including biotechnology. These transactions are typically non-discretionary and often pre-scheduled under Rule 10b5-1 plans.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in the executive's view of the company's prospects.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations from vested restricted stock units. It does not provide new fundamental information about Lyell Immunopharma's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this event does not alter the underlying investment thesis.

Keywords

Lyell Immunopharma, LYEL, Insider Trading, Form 4, Stock Sale, CEO, Lynn Seely, Tax Withholding, Restricted Stock Units, Biotechnology